Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3...

Area of Science:

• Oncology
• Immunotherapy
• Clinical Trials

Background:

• Extensive-stage small cell lung cancer (ES-SCLC) presents a significant clinical challenge with poor patient prognoses.
• Current first-line treatments for ES-SCLC have limitations, highlighting the need for novel therapeutic strategies.

Purpose of the Study:

• To evaluate the efficacy and safety of toripalimab combined with etoposide and platinum-based chemotherapy (EP) as a first-line treatment for ES-SCLC.
• To compare this combination regimen against placebo plus EP in a phase 3 randomized clinical trial.

Main Methods:

• A multicenter, double-blind, placebo-controlled phase 3 randomized clinical trial (EXTENTORCH study) enrolled 442 patients with ES-SCLC.
• Patients received either toripalimab plus EP or placebo plus EP, followed by maintenance therapy.
• Primary endpoints included investigator-assessed progression-free survival (PFS) and overall survival (OS); correlative biomarkers were identified via whole-exome sequencing.

Main Results:

• Toripalimab plus EP significantly improved PFS (HR, 0.67) and reduced the risk of death (HR, 0.80) compared to placebo plus EP.
• Median OS was 14.6 months with toripalimab versus 13.3 months with placebo.
• Specific genetic biomarkers (low intratumor heterogeneity, certain haplotypes, and gene variations) correlated with favorable outcomes in the toripalimab group. Safety profiles were comparable, with similar rates of severe adverse events.

Conclusions:

• Adding toripalimab to first-line EP chemotherapy demonstrates significant clinical benefits in PFS and OS for ES-SCLC patients.
• The combination regimen exhibits an acceptable safety profile.
• Toripalimab plus EP represents a promising new treatment option for patients diagnosed with ES-SCLC.